Therapeutic Management of a Substantial Pelvic Aneurysmatic Bone Cyst Including the Off-Label Use of Denosumab in a 35-Year-Old Female Patient

<div>Follow-up CT scan of the pelvis showing stable disease after discontinuation of the second cycle of Denosumab treatment for fifteen months.</div>

Case Reports in Orthopedics

fig3

Figure 3

Figure 3: Therapeutic Management of a Substantial Pelvic Aneurysmatic Bone Cyst Including the Off-Label Use of Denosumab in a 35-Year-Old Female Patient 

Figure 3 | Therapeutic Management of a Substantial Pelvic Aneurysmatic Bone Cyst Including the Off-Label Use of Denosumab in a 35-Year-Old Female Patient 